Michael J. Kimber

Michael J. Kimber

Auto-generated profile, based on publicly available information

Michael J. Kimber

Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2015 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MZMostafa Zamanian
Mostafa Zamanian
LFLisa M Fraser
Lisa M Fraser
PAPrince N Agbedanu
Prince N Agbedanu
HHHiruni Harischandra
Hiruni Harischandra
AMAndrew R Moorhead
Andrew R Moorhead
MKMichael J Kimber
Michael J Kimber
Lymphatic filariasis (LF) is a socio-economically devastating mosquito-borne Neglected Tropical Disease caused by parasitic filarial nematodes. The interaction between the parasite and host, both mosquito and human, during infection, development and persistence is dynamic and delicately balanced. Manipulation of this interface to the detriment of the parasite is a promising potential avenue to develop disease therapies but is prevented by our very limited understanding of the host-parasite relationship. Exosomes are bioactive small vesicles (30–120 nm) secreted by a wide range of cell types and involved in a wide range of physiological processes. Here, we report the identification and partial characterization of exosome-like vesicles (ELVs) released from the infective L3 stage of the human filarial parasite Brugia malayi. Exosome-like vesicles were isolated from parasites in culture media and electron microscopy and nanoparticle tracking analysis were used to confirm that vesicles produced by juvenile B. malayi are exosome-like based on size and morphology. We show that loss of parasite viability correlates with a time-dependent decay in vesicle size specificity and rate of release. The protein cargo of these vesicles is shown to include common exosomal protein markers and putative effector proteins. These Brugia-derived vesicles contain small RNA species that include microRNAs with host homology, suggesting a potential role in host manipulation. Confocal microscopy shows J774A.1, a murine macrophage cell line, internalize purified ELVs, and we demonstrate that these ELVs effectively stimulate a classically activated macrophage phenotype in J774A.1. To our knowledge, this is the first report of exosome-like vesicle release by a human parasitic nematode and our data suggest a novel mechanism by which human parasitic nematodes may actively direct the host responses to infection. Further interrogation of the makeup and function of these bioactive vesicles could seed new therapeutic strategies and unearth stage-specific diagnostic biomarkers. Lymphatic filariasis is caused by parasitic nematodes that invade and occupy the host lymphatic system. The extent of lymphatic filariasis is staggering, with over 120 million people infected in 73 endemic countries and an estimated 40 million people suffering from a range of disfiguring and debilitating clinical manifestations of this disease. The mechanisms by which these medically important parasites navigate the host immune response to establish infection are not yet fully understood. In this study, we identify exosome-like vesicles (ELVs) that are abundantly released from infective stage L3 Brugia malayi, an etiological agent of human lymphatic filariasis. We show that these vesicles have a narrow size distribution and morphology consistent with classical exosomes, and that they contain common exosomal protein markers, putative effector proteins, as well as small regulatory RNAs. We show that ELVs are enriched with microRNAs that are perfectly conserved between parasite and host, suggesting a potentially novel mechanism by which filarial worms can actively manipulate host gene expression. We demonstrate that parasite ELVs are internalized by macrophages and elicit a classically activated phenotype in these host cells. The discovery of exosome-like vesicle release by human nematode parasites newly enlightens the roadmap to understanding the pathology of LF and related helminthiases. These vesicles also present promising new targets for intervention and diagnostics.

16 April 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
HHHiruni Harischandra
Hiruni Harischandra
WYWang Yuan
Wang Yuan
HLHannah J Loghry
Hannah J Loghry
MZMostafa Zamanian
Mostafa Zamanian
MKMichael J Kimber
Michael J Kimber
The filarial nematode Brugia malayi is an etiological agent of Lymphatic Filariasis. The capability of B. malayi and other parasitic nematodes to modulate host biology is recognized but the mechanisms by which such manipulation occurs are obscure. An emerging paradigm is the release of parasite-derived extracellular vesicles (EV) containing bioactive proteins and small RNA species that allow secretion of parasite effector molecules and their potential trafficking to host tissues. We have previously described EV release from the infectious L3 stage B. malayi and here we profile vesicle release across all intra-mammalian life cycle stages (microfilariae, L3, L4, adult male and female worms). Nanoparticle Tracking Analysis was used to quantify and size EVs revealing discrete vesicle populations and indicating a secretory process that is conserved across the life cycle. Brugia EVs are internalized by murine macrophages with no preference for life stage suggesting a uniform mechanism for effector molecule trafficking. Further, the use of chemical uptake inhibitors suggests all life stage EVs are internalized by phagocytosis. Proteomic profiling of adult male and female EVs using nano-scale LC-MS/MS described quantitative and qualitative differences in the adult EV proteome, helping define the biogenesis of Brugia EVs and revealing sexual dimorphic characteristics in immunomodulatory cargo. Finally, ivermectin was found to rapidly inhibit EV release by all Brugia life stages. Further this drug effect was also observed in the related filarial nematode, the canine heartworm Dirofilaria immitis but not in an ivermectin-unresponsive field isolate of that parasite, highlighting a potential mechanism of action for this drug and suggesting new screening platforms for anti-filarial drug development. Brugia malayi is a parasitic nematode and etiological agent of Lymphatic Filariasis (LF), a mosquito-borne Neglected Tropical Disease affecting approximately 120 million people globally. Brugia and other parasitic nematodes have the ability to modulate host biology and evade the immune response but the mechanisms by which they do this are unclear. One possibility is via immunomodulatory proteins and small RNAs packaged and released in extracellular vesicles (EV) that target host cells. Here we show that all Brugia life stages relevant to human infection release EVs that are internalized by murine macrophages. These EVs contain immunomodulatory proteins and show sex-specific differences in cargo providing insight into how B. malayi establishes and maintains infection. Critically, we show ivermectin, a drug used to treat LF and related diseases affects EV release, which provides new insight into how these drugs work and identifies a new screening paradigm to help identify future anti-parasitic drugs.

6 December 2011 in BMC Genomics
Verified
Journal Article
Open access
PDF file
MZMostafa Zamanian
Mostafa Zamanian
MKMichael J Kimber
Michael J Kimber
PMPaul McVeigh
Paul McVeigh
SCSteve Carlson
Steve Carlson
AMAaron G Maule
Aaron G Maule
TDTim A Day
Tim A Day
G protein-coupled receptors (GPCRs) constitute one of the largest groupings of eukaryotic proteins, and represent a particularly lucrative set of pharmaceutical targets. They play an important role in eukaryotic signal transduction and physiology, mediating cellular responses to a diverse range of extracellular stimuli. The phylum Platyhelminthes is of considerable medical and biological importance, housing major pathogens as well as established model organisms. The recent availability of genomic data for the human blood fluke Schistosoma mansoni and the model planarian Schmidtea mediterranea paves the way for the first comprehensive effort to identify and analyze GPCRs in this important phylum.

30 August 2018 in ACS Sensors
Verified
Journal Article
Closed access
YWYifei Wang
Yifei Wang
WYWang Yuan
Wang Yuan
MKMichael Kimber
Michael Kimber
MLMeng Lu
Meng Lu
Liang DongLiang Dong
Liang Dong

10 December 2020 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
HLHannah J. Loghry
Hannah J. Loghry
WYWang Yuan
Wang Yuan
MZMostafa Zamanian
Mostafa Zamanian
NWNicolas J. Wheeler
Nicolas J. Wheeler
TDTimothy A. Day
Timothy A. Day
MKMichael J. Kimber
Michael J. Kimber
Lymphatic filariasis (LF) is a disease caused by parasitic filarial nematodes that is endemic in 49 countries of the world and affects or threatens over 890 million people. Strategies to control LF rely heavily on mass administration of anthelmintic drugs including ivermectin (IVM), a macrocyclic lactone drug considered an Essential Medicine by the WHO. However, despite its widespread use the therapeutic mode of action of IVM against filarial nematodes is not clear. We have previously reported that filarial nematodes secrete extracellular vesicles (EVs) and that their cargo has immunomodulatory properties. Here we investigate the effects of IVM and other anti‐filarial drugs on parasitic nematode EV secretion, motility, and protein secretion. We show that inhibition of EV secretion was a specific property of IVM, which had consistent and significant inhibitory effects across nematode life stages and species, with the exception of male parasites. IVM inhibited EV secretion, but not parasite motility, at therapeutically relevant concentrations. Protein secretion was inhibited by IVM in the microfilariae stage, but not in any other stage tested. Our data provides evidence that inhibiting the secretion of immunomodulatory EVs by parasitic nematodes could explain, at least in part, IVM mode of action and provides a phenotype for novel drug discovery.

23 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SMSarah Minkler
Sarah Minkler
Fabrice LucienFabrice Lucien
Fabrice Lucien
MKMichael J. Kimber
Michael J. Kimber
Dipak Kumar SahooDipak Kumar Sahoo
Dipak Kumar Sahoo
ABAgnes Bourgois-Mochel
Agnes Bourgois-Mochel
Jonathan MochelJonathan Mochel
Jonathan Mochel
Urinary bladder cancer (UBC) is the most common malignancy of the urinary tract in humans, with an estimated global prevalence of 1.1 million cases over 5 years. Because of its high rates of recurrence and resistance to chemotherapy, UBC is one of the most expensive cancers to treat, resulting in significant health care costs. The development of innovative molecular and cellular tools is necessary to refine patient stratification and help predict response to treatment. Urine is an underused resource of biological components shed from bladder tumors, such as exfoliated cells and extracellular vesicles, that could serve as molecular fingerprints and provide valuable biological insights into tumor phenotype and mechanisms of resistance to chemotherapy. Additionally, characterization of urine-derived extracellular vesicles and cells could be used as reliable biomarkers for prediction of response to neoadjuvant therapy.